Stock data
Mineralys Therapeutics, Inc. (MLYS)
Mineralys Therapeutics, Inc. (MLYS) reported net income of -US$154.65M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | — | — | -US$170.60M | -US$154.65M | — |
| 2024 | — | — | -US$192.40M | -US$177.81M | — |
| 2023 | — | — | -US$84.66M | -US$71.90M | — |
| 2022 | — | — | -US$31.48M | -US$29.80M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | — | -US$241.07M | — |
| 2026-03-31 | — | -US$39.34M | — |
| 2025-12-31 | — | -US$32.23M | — |
| 2025-09-30 | — | -US$36.93M | — |
| 2025-06-30 | — | -US$43.27M | — |
| 2025-03-31 | — | -US$42.21M | — |
| 2024-12-31 | — | -US$48.95M | — |
| 2024-09-30 | — | -US$56.34M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.